4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

Nicole DeFeudis

Editor

4D Molecular Therapeutics announced Wednesday that its inhalable gene therapy for cystic fibrosis showed signs of improved quality of life in an early look from its Phase I dose exploration study.

The drug, 4D-710, is delivered via nebulizer and is designed to achieve expression of a protein called CFTR in lung airway epithelial cells. CFTR helps keep the balance between salt and water on surfaces including the lung, but a malfunction of the protein can lead to the accumulation of a thick mucus that causes some of the symptoms behind cystic fibrosis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...

4DMT's in­hal­able gene ther­a­py for cys­tic fi­bro­sis shows ear­ly pos­i­tive signs in tiny group of pa­tients

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

FDA rolls out long-await­ed pro­pos­al to over­haul di­ag­nos­tics reg­u­la­tion

De­spite a sum­mer of block­buster rounds, biotech fund­ing is on track to lev­el off at pre-pan­dem­ic norms

FDA un­veils new rare dis­ease pi­lot pro­gram to in­crease agency-spon­sor com­mu­ni­ca­tions

How aca­d­e­m­ic cen­ters are try­ing to keep their promis­ing drug dis­cov­er­ies out of the ‘val­ley of death’

In the race to get type 1 pa­tients off in­sulin, fo­cus turns to cell trans­plants and in­sulin-pro­duc­ing stem cells

CMIC: Japan’s first and largest CRO con­tin­ues 30-year evo­lu­tion to help glob­al spon­sors nav­i­gate the com­plex lo­cal ...

4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients

FDA rolls out long-awaited proposal to overhaul diagnostics regulation

Despite a summer of blockbuster rounds, biotech funding is on track to level off at pre-pandemic norms

FDA unveils new rare disease pilot program to increase agency-sponsor communications

How academic centers are trying to keep their promising drug discoveries out of the ‘valley of death’

In the race to get type 1 patients off insulin, focus turns to cell transplants and insulin-producing stem cells

CMIC: Japan’s first and largest CRO continues 30-year evolution to help global sponsors navigate the complex local ...